These patients would be ideally apt to benefit from therapeutics that directly affect IL1β signaling like the mAb gevokizumab (68), which is currently being tested for metastatic colorectal, gastroesophageal, and renal cancers in a phase Ib study (NCT03798626) and for patients with colon cancer in a phase II/III study (NCT05178576) upon previous screening by ctDNA. Here, IL1B is linked to colonic neoplasm.